WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, May 27, 2020

Information

Tags:

Medical specialties, Medicine, Lymphatic system, Stem cells, Hematopoiesis, Cancer treatments, Cancer immunotherapy, Bone marrow, Immunotherapy, Immunology, Lymphocyte, Shimon Slavin

Geotags:

Philadelphia, Pa, Us

Organisation:

WINDMIL THERAPEUTICS

Summary

Key Points:

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
The companys proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence. For more information, please visit: https://windmiltx.com.

WindMIL Therapeutics Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
[email protected]